Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK) - Report - MDSpire
Clinical Report: Guidelines for the Management of ATTR-CM in Germany
Background
ATTR-CM is increasingly recognized as a significant cause of heart failure. In Germany, two classes of agents—TTR stabilizers and TTR gene silencers—are approved for treatment.
Data Highlights
In clinical studies, tafamidis has demonstrated a 30% reduction in all-cause mortality and a significant decrease in cardiovascular-related hospitalizations. Acoramidis has shown promising results in improving quality of life metrics and functional capacity in patients with ATTR-CM. Vutrisiran has been associated with a reduction in cardiac amyloid deposits and improved echocardiographic parameters.
Key Findings
Three agents are approved for ATTR-CM treatment in Germany: tafamidis, acoramidis, and vutrisiran.
Tafamidis has shown efficacy in reducing all-cause mortality and cardiovascular-related hospitalizations in the ATTR-ACT trial.
Long-term data indicate survival benefits for patients treated with tafamidis compared to those who started treatment later.
Safety profiles for tafamidis are comparable to placebo, with no dose-related safety signals reported.
Individualized treatment decisions are necessary due to the lack of head-to-head trials among the approved agents.
Clinical Implications
Clinicians should consider the individual characteristics of patients when selecting treatment for ATTR-CM, as the efficacy and safety profiles of available therapies vary. Early initiation of therapy may enhance patient outcomes.
Conclusion
The guidelines provide a framework for managing ATTR-CM in Germany. The study concluded that early treatment with TTR stabilizers, particularly tafamidis, significantly improves survival rates and reduces hospitalizations in patients with ATTR-CM. Additionally, it highlighted the importance of personalized treatment approaches, considering the varying efficacy and safety profiles of the available therapies.
Related Resources & Content
German Society of Amyloid Diseases and German Cardiac Society, 2025 -- Guidelines for the Management of ATTR-CM in Germany
Clinical Research in Cardiology — Guidelines for the Diagnosis and Management of Cardiac Amyloidosis: A Consensus Statement from the German Cardiac Society (DGK)
JAMA Cardiology — Impact of Acoramidis on Health Outcomes in Heart Failure: Insights from a Secondary Analysis of the ATTRibute-CM Study
Clinical Research in Cardiology — Evaluating the Diagnostic Utility of Cardiovascular Magnetic Resonance Versus Endomyocardial Biopsy in Cardiac Amyloidosis: A Multi-Center Analysis
Clinical Research in Cardiology — Pathophysiological Mechanisms and Treatment Approaches in Cardiac Amyloidosis: Is Inflammation a Contributing Factor?
Beyonttra | European Medicines Agency (EMA)
Vyndaqel, INN-tafamidis | European Medicines Agency (EMA)
Zusammenfassende Dokumentation
Nutzenbewertungsverfahren zum Wirkstoff Vutrisiran (Neues Anwendungsgebiet: Wildtyp- oder hereditäre Transthyretin-Amyloidose mit Kardiomyopathie) - Gemeinsamer Bundesausschuss
Nuklearkardiologie – Aktueller Stand der klinischen Anwendung | Die Kardiologie | Springer Nature Link
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy - PubMed
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial
New Concise Clinical Guidance Addresses Evaluation and Management of ATTR-CM - American College of Cardiology
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis - PMC
Relative efficacy of acoramidis, tafamidis and vutrisiran in patients with transthyretin amyloid cardiomyopathy: a multilevel network meta-regression | European Journal of Heart Failure | Oxford Academic
Eplontersen trial did not meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy
Eplontersen for Transthyretin Amyloid Cardiomyopathy | New England Journal of Medicine
by Fabian aus dem Siepen, Teresa Trenkwalder, Birgit Aßmus, Ingrid Kindermann, Daniel Lavall, Sebastian Spethmann, Lars Michel, Timon Hansen, Sebastian Kruck, Christoph Rischpler, Fabian Knebel, Stéphanie K. Schwarting, Udo Bavendiek, Maria Papathanasiou, Ute Hegenbart, Ali Yilmaz, Katrin Hahn, Alexander Carpinteiro, Roman Pfister, Caroline Morbach
A nationwide German claims analysis found lower initiation of guideline-recommended sodium-glucose cotransporter-2 inhibitors among women and patients living in lower-income municipalities.
Three of 23 patients experienced heart failure deterioration following medication withdrawal, while adverse drug events occurred only among patients who continued therapy.
In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.
